(Q43898828)

27 November 2017

Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma (English)

1 reference

27 November 2017

1 reference

David S Pearlman

1

1 reference

27 November 2017

Martha V White

2

1 reference

27 November 2017

Allen K Lieberman

3

1 reference

27 November 2017

Pamela J Pepsin

4

1 reference

27 November 2017

Chris Kalberg

5

1 reference

27 November 2017

Amanda Emmett

6

1 reference

27 November 2017

Brian Bowers

7

1 reference

27 November 2017

Kathleen A Rickard

8

1 reference

27 November 2017

Paul Dorinsky

9

1 reference

27 November 2017

1 February 2002

1 reference

Annals of Allergy, Asthma & Immunology

27 November 2017

1 reference

27 November 2017

88

1 reference

27 November 2017

227-235

1 reference

27 November 2017

2

1 reference

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Measuring quality of life in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Salmeterol enhances the inhibitory activity of dexamethasone on allergen-induced blood mononuclear cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Asthma guidelines: an assessment of physician understanding and practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962001-7

7 January 2021

10.1016/S1081-1206(10)62001-7

Identifiers

DOI

1 reference

27 November 2017

1 reference